Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Short Report
22 May 2024

Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals

Authors: Maher S Moazin, Abdulaziz Baazeem, Ayman Al-Bakri, Adel Al Dayel, Ashraf Amir, Saud Al Sifri, Mona Reda, Fahad Bashraheel, Abdullah Alfakhri, Yousef Hamdy [email protected], and Fayez ElshaerAuthor Info & Affiliations
Volume 13, Number 7
https://doi.org/10.57264/cer-2023-0155
PDFFormats

Abstract

Aim: Erectile dysfunction (ED) is marked by a recurring incapacity to achieve or uphold a satisfactory erection during sexual activities. The study aims to increase awareness about male reproductive health, dispel misconceptions about ED and encourage physician-patient discussions. Materials & methods: A live online poll was conducted during a 3-day webinar titled “Turning the Tide of Men's Health” organized by Viatris™ in collaboration with the Saudi Society of Family and Community Medicine and attended by healthcare professionals (HCPs) from diverse specialties. The attendees voluntarily responded to nine poll questions on adherence to ED medication, use of phosphodiesterase type 5 inhibitors (PDE5is) as cure versus management of ED and patients' challenges. The responses to the poll questions were recorded and assessed to understand the perceptions of HCPs. Results: The poll garnered 10,423 responses from 5831 attendees on the second day of the webinar. The key findings included HCPs' perceptions that PDE5is contribute to ED management not complete cure. The respondents acknowledged that adherence to ED medications might decline on days without planned sexual activity, and long-term adherence on a daily PDE5i is exhibited by a relatively modest percentage of ED patients. The consensus among respondents was that PDE5is do not enhance or generate sexual desire, and the daily schedule of ED treatment may be burdensome for some patients. Conclusion: The findings from this poll offer insights into the perspectives of HCPs regarding the usage of PDE5is to treat ED. Responders of the poll generally agreed that PDE5is can help manage ED without affecting desire, though adherence may be lower on days without planned sexual activity. Furthermore, most respondents acknowledged that adhering to a daily pill regimen posed a greater burden than waiting for the medication to take effect.

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

Papers of special note have been highlighted as: • of interest
1.
Wang CM, Wu BR, Xiang P, Xiao J, Hu XC. Management of male erectile dysfunction: from the past to the future. Front. Endocrinol. (Lausanne). 14, 1148834 (2023).
PubMed
Google Scholar
• This recently published review highlights the current therapies for erectile dysfunction (ED) management and the need for large-scale, clinical studies for the new therapeutics.
2.
Mitidieri E, Cirino G, d'Emmanuele di Villa Bianca R, Sorrentino R. Pharmacology and perspectives in erectile dysfunction in man. Pharmacol. Ther. 208, 107493 (2020).
PubMed
Google Scholar
3.
Tandon A. Psychosexual health and sexuality: multidisciplinary considerations in clinical practice. J. Psychosexual Health. 5(2), 106–113 (2023).
Google Scholar
• This viewpoint article summarizes the general medical conditions and systemic disorders that are often associated with sexual disorders.
4.
Maestre-Lorén F, Castillo-Garayoa JA, López-i-Martín X, Sarquella-Geli J, Andrés A, Cifre I. Psychological distress in erectile dysfunction: the moderating role of attachment. Sex. Med. 9(5), 100436 (2021).
PubMed
Google Scholar
5.
Topak OZ, Sinik Z, Oguzhanoglu NK, Ugurlu TT. An evaluation of psychogenic predictors of non-organic erectile dysfunction. Medicina. (Kaunas). 59(7), 1195 (2023).
PubMed
Google Scholar
6.
Azad AK, Setunge S, Selim S et al. Dyslipidaemia as a risk factor for erectile dysfunction in Type 2 diabetes mellitus patients. Diabetes Metab. Syndr. 13(1), 748–753 (2019).
PubMed
Google Scholar
7.
El-Sakka AI. Erectile dysfunction in Arab countries. Part I: prevalence and correlates. Arab J. Urol. 10(2), 97–103 (2012).
PubMed
Google Scholar
8.
Scherzer ND, Le TV, Hellstrom WJG. Sildenafil's impact on male infertility: what has changed in 20 years? Int. J. Impot. Res. 31(2), 71–73 (2019).
PubMed
Google Scholar
9.
Moncada I, Martinez-Salamanca J, Ruiz-Castañe E, Romero J. Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. Int. J. Impot. Res. 30(5), 203–208 (2018).
PubMed
Google Scholar
10.
Hawksworth DJ, Burnett AL. Pharmacotherapeutic management of erectile dysfunction. Clin. Pharmacol. Ther. 98(6), 602–610 (2015).
PubMed
Google Scholar
11.
Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 96(3), 257–280 (2005).
PubMed
Google Scholar
12.
Salonia ABC, Capogrosso P, Carvalho J; EAU Guidelines et al. In The EAU Annual Congress Milan. EAU Guidelines Office, Arnhem, The Netherlands (2023). Available at: https://uroweb.org/guidelines/sexual-and-reproductive-health
Google Scholar
• The European Association of Urology guideline (2023) presents an overview of all aspects related to sexual and reproductive health in adult men. The guidelines reflect the evidence accessible to experts.
13.
Corona G, Cucinotta D, Di Lorenzo G et al. The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction. J.Endocrinol. Invest. 46(6), 1241–1274 (2023).
PubMed
Google Scholar
14.
Lue TF. Erectile dysfunction. N. Engl. J. Med. 342(24), 1802–1813 (2000).
PubMed
Google Scholar
15.
Behr-Roussel D, Gorny D, Mevel K et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur. Urol. 47(1), 87–91 (2005).
PubMed
Google Scholar
16.
Kovanecz I, Rambhatla A, Ferrini MG et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int. 101(2), 203–210 (2008).
PubMed
Google Scholar
17.
Pattanaik S, Kaundal P, Mavuduru RS, Singh SK, Mandal AK. Endothelial dysfunction in patients with erectile dysfunction: a double-blind, randomized-control trial using tadalafil. Sex Med. 7(1), 41–47 (2019).
PubMed
Google Scholar
18.
D'Andrea S, Barbonetti A, Martorella A, Necozione S, Francavilla F, Francavilla S. Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: a systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials. Int. J. Clin. Pract. 73(2), e13296 (2019).
PubMed
Google Scholar
19.
Jannini EA, Isidori AM, Gravina GL et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J. Sex. Med. 6(9), 254725–254760 (2009).
Google Scholar
20.
Carvalheira AA, Pereira NM, Maroco J et al. Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. J. Sex. Med. 9(9), 2361–2369 (2012).
PubMed
Google Scholar
21.
Forgue ST, Patterson BE, Bedding AW et al. Tadalafil pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 61(3), 280–288 (2006).
PubMed
Google Scholar
22.
Smith WB 2nd, McCaslin IR, Gokce A, Mandava SH, Trost L, Hellstrom WJ. PDE5 inhibitors: considerations for preference and long-term adherence. Int. J. Clin. Pract. 67(8), 768–780 (2013).
PubMed
Google Scholar
23.
Carvalheira A, Forjaz V, Pereira NM. Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors? Sex. Med. 2(2), 96–102 (2014).
PubMed
Google Scholar
• This is an important study that highlights the factors that influence adherence to phosphodiesterase type 5 inhibitors.
24.
MacDonald SM, Burnett AL. Physiology of erection and pathophysiology of erectile dysfunction. Urol. Clin. North Am. 48(4), 513–525 (2021).
PubMed
Google Scholar
25.
Najari BB, Kashanian JA. Erectile dysfunction. JAMA 316(17), 1838 (2016).
PubMed
Google Scholar
26.
Muise A, Schimmack U, Impett EA. Sexual frequency predicts greater well-being, but more is not always better. Soc. Psychol. Pers. Sci. 7(4), 295–302 (2016).
Google Scholar
• In this study, researchers do a comparative analysis of three studies, highlighting that sexual frequency does not significantly affect well being.
27.
Goldstein I, Giraldi A, Maculaitis MC, Li VW, Hartzell-Cushanick R, Hassan TA. Real-world assessment of the impact of erectile dysfunction on sexual planning behavior and health- and treatment-related outcomes among men in 8 countries. Sex Med. 8(3), 338–349 (2020).
PubMed
Google Scholar
28.
Mulhall JP, Hassan TA, Rienow J. Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries. Int J Clin Pract. 72(4), e13074 (2018).
PubMed
Google Scholar
• This is a survey-based study on men with ED from seven countries and was aimed at understanding patients' sexual habits and behaviors which could enable clinical practitioners in selecting the suitable ED medication.
|